Sleep apnea treatment begins with an objective test and a severity grade, and the usual first-line option for obstructive sleep apnea is positive airway pressure (CPAP), which lowered the apnea-hypopnea index from 29.0 to 3.7 events per hour in a large trial, though its users averaged only 3.3 hours a night. Oral appliances, positional devices, weight loss, hypoglossal nerve stimulation and upper airway surgery each have published evidence for particular groups of people, from randomized trials for some options to an uncontrolled cohort for nerve stimulation and mostly case series for surgery. This page summarizes that evidence; the choice belongs to a patient and a sleep physician.
Sleep apnea treatment starts with a diagnosis and a severity grade, and the options after that range from positive airway pressure (CPAP) through oral appliances, positional devices and weight loss to nerve stimulation and surgery. This page describes what guidelines and trials report for each option and how obstructive sleep apnea treatment usually runs in adults. It is an overview of research, not advice to choose one thing, and the choice sits between you and a sleep physician.
Related pages cover other parts of the topic. Types of sleep apnea explains why obstructive and central apnea are treated differently, Home test for sleep apnea covers the testing step, and Sleep apnea natural treatments covers the lifestyle and exercise end. They are covered in more depth there.
Sleep apnea treatment: the care path from test to option
Obstructive sleep apnea (OSA) is common. A literature-based analysis funded by ResMed estimated that 936 million adults aged 30 to 69 have mild to severe OSA (an apnea-hypopnea index, AHI, of 5 or more events per hour) and 425 million have moderate to severe OSA (15 or more).
Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019. PMID 31300334
The care path behind sleep apnea OSA treatment has a fixed order, and treatment comes only after the test and the severity grade.
| Step | What happens | What the guideline says |
|---|---|---|
| 1. Suspicion | Snoring, witnessed breathing pauses, daytime sleepiness | Suspicion should trigger a comprehensive sleep evaluation |
| 2. Objective test | Polysomnography in a sleep lab, or a home sleep apnea test with an adequate device | Questionnaires and prediction tools should not be used alone to diagnose; a negative or inconclusive home test is followed by polysomnography |
| 3. Severity grade | The AHI (apneas and hypopneas per hour of sleep) | Presence and severity must be known before treatment, to choose it and as a baseline |
| 4. Option | Positive airway pressure, oral appliance, behavioral measures, surgery, adjuncts | Chosen together with the patient |
| 5. Follow-up | Check of use and efficacy data; repeat testing for some options | Chronic disease with long-term care |
Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009. PMID 19960649
Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017. PMID 28162150
Severity is graded by the AHI: mild is 5 to 14, moderate 15 to 29 and severe 30 or more events per hour, the bands used in a 2025 review of US prevalence that applied the 4% oxygen-desaturation scoring rule; other scoring rules shift the count. In the trials below, an AHI of 15 or more is the usual line for moderate-to-severe apnea. The OSA treatment options fall into five groups, and the sections that follow take them in the order most guidelines present them: CPAP first, then its alternatives.
Sönmez I, Vo Dupuy A, Yu KS, et al. Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States. Respir Med 2025. PMID 40957495
CPAP for sleep apnea and what the evidence supports
CPAP holds the airway open with a steady stream of air from a bedside machine through a mask. The 2019 guideline of the American Academy of Sleep Medicine on positive airway pressure makes a strong recommendation to use it, compared with no therapy, for adults with obstructive sleep apnea and excessive sleepiness, and conditional suggestions for people with impaired sleep-related quality of life or with high blood pressure. It recommends that either CPAP or auto-adjusting pressure (APAP) be used for ongoing treatment and that education be given when treatment starts; it suggests behavioral and troubleshooting help during the first weeks. As good practice statements it says that treatment should rest on a diagnosis from objective testing and that follow-up, including troubleshooting and checks of use and efficacy data, should take place.
Patil SP, Ayappa IA, Caples SM, et al. Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2019. PMID 30736887
The SAVE trial randomized 2,717 adults aged 45 to 75 with moderate-to-severe apnea and existing heart or brain-vessel disease to CPAP plus usual care or usual care alone. In the CPAP group the AHI fell from 29.0 to 3.7 events per hour, and CPAP reduced snoring and daytime sleepiness and improved quality of life and mood. But after a mean follow-up of 3.7 years, cardiovascular events occurred in 17.0% of the CPAP group and 15.4% of the usual-care group (hazard ratio 1.10, 95% confidence interval 0.91 to 1.32), so CPAP did not prevent them in this population. The participants used it for 3.3 hours a night on average, and most had minimal sleepiness, which limits what the trial can say about people with strong symptoms.
McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med 2016. PMID 27571048
Use is the weak point. A review in Proceedings of the American Thoracic Society found that, when adherence is defined as more than 4 hours of use a night, 46 to 83% of patients have been reported as non-adherent. The review states that evidence suggests use for more than 6 hours decreases sleepiness, improves daily functioning and restores memory to normal levels, and that the decision to embrace CPAP appears to be made in the first few days. It found few data supporting the many products marketed to improve use, and emerging data suggesting that behavioral interventions may help.
Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 2008. PMID 18250209
Sleep apnea CPAP alternatives at a glance
The alternatives are not one group. Each has been studied in a different kind of patient, and the trials measure different things, so the table is a map of the evidence, not a ranking.
| Option | Who was studied | What changed | Main limit |
|---|---|---|---|
| Oral appliance | Adults with OSA, many moderate to severe | AHI fell less than with CPAP, reported use was higher | Needs dental fitting and follow-up; less efficacious on AHI |
| Positional therapy | Adults whose apnea is position dependent | AHI 54% lower in a pooled analysis | Short-term data; long-term use unknown |
| Weight loss | Adults who are overweight or obese | AHI fell in proportion to weight lost | Effects shrink over time in the longest study |
| Hypoglossal nerve stimulation | Moderate to severe OSA, CPAP difficulty, BMI under 32 | Median AHI 29.3 to 9.0 at 12 months | Implant surgery; strict selection; mostly uncontrolled data |
| Upper airway surgery | Adults seeking an alternative to PAP | Maxillomandibular advancement lowered AHI consistently | Mostly case series; pharyngeal operations less consistent |
Oral appliance for sleep apnea and the dental route
A mandibular advancement device holds the lower jaw forward during sleep. The 2015 guideline of the American Academy of Sleep Medicine and the American Academy of Dental Sleep Medicine recommends that sleep physicians consider prescribing an oral appliance, rather than no treatment, for adults with OSA who are intolerant of CPAP or prefer another therapy. It suggests a custom, titratable appliance fitted by a qualified dentist rather than a non-custom device, dental follow-up for side effects, and follow-up sleep testing to confirm that it works.
Ramar K, Dort LC, Katz SG, et al. Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. J Clin Sleep Med 2015. PMID 26094920
A direct randomized comparison is a crossover trial in 126 patients with moderate-to-severe OSA (mean AHI 25.6), of whom 108 completed both treatments for one month each. CPAP lowered the AHI more (4.5 against 11.1 events per hour), but the patients reported higher use with the appliance (6.5 against 5.2 hours a night). Sleepiness, driving-simulator performance and disease-specific quality of life improved by similar amounts on both, and 24-hour blood pressure was not worse with the appliance, although neither treatment improved it. The authors suggested that CPAP's greater efficacy was offset by its poorer use. One month is short, so the trial says nothing about years.
Phillips CL, Grunstein RR, Darendeliler MA, et al. Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2013. PMID 23413266
Positional therapy for apnea that is worse on the back
In many people the number and length of apneas depend on body position, with more events lying on the back. A systematic review put this at approximately 56 to 75% of patients with OSA. The newer positional devices, worn on the neck or chest, give a gentle vibration that discourages sleeping on the back. The review pooled three cohort studies and four randomized trials. The pooled AHI was lower by 11.3 events per hour (a 54% reduction), and time spent on the back fell by 33.6% of total sleep time (an 84% reduction). Use was high in the study period, but the authors stated that long-term use could not be judged for lack of reliable data.
Ravesloot MJL, White D, Heinzer R, et al. Efficacy of the New Generation of Devices for Positional Therapy for Patients With Positional Obstructive Sleep Apnea: A Systematic Review of the Literature and Meta-Analysis. J Clin Sleep Med 2017. PMID 28212691
The practical reading is narrow. Positional therapy has evidence for people whose sleep study shows position-dependent apnea, and the data are short-term. The question of which sleeping position suits which problem has its own page: Best position to sleep in for sleep apnea.
Weight loss and sleep apnea in the studies
Excess weight is the best-known modifiable risk factor, and three kinds of study speak to it. A population cohort in Wisconsin followed 690 randomly selected employed adults for four years between examinations. Relative to stable weight, a 10% weight loss predicted a 26% decrease in AHI (95% confidence interval 18 to 34%), and a 10% weight gain predicted a 32% increase (20 to 45%).
Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000. PMID 11122588
A randomized trial in 72 overweight adults with mild OSA compared a very-low-calorie diet with supervised lifestyle counseling against routine counseling. Body weight in the intervention group fell by 10.7 kg on average, the groups differed significantly in the change in AHI (P = 0.017), and the benefits held at one year.
Tuomilehto HP, Seppä JM, Partinen MM, et al. Lifestyle intervention with weight reduction: first-line treatment in mild obstructive sleep apnea. Am J Respir Crit Care Med 2009. PMID 19011153
The longest follow-up is Sleep AHEAD, in adults with overweight or obesity, type 2 diabetes and OSA, who were randomized to intensive lifestyle intervention or diabetes education; 134 of the 264 had a polysomnogram at 10 years. The AHI was lower with the intervention by 9.7, 8.0 and 7.9 events per hour at 1, 2 and 4 years, and by 4.0 at 10 years (P = 0.109, not significant). Remission of OSA at 10 years was more common with the intervention (34.4%) than with education (22.2%). The intervention group's advantage shrank as weight came back (10.7 kg lost at 1 year, 7.1 kg at 10 years), while the change in AHI over time stayed related to the amount of weight lost.
Kuna ST, Reboussin DM, Strotmeyer ES, et al. Effects of Weight Loss on Obstructive Sleep Apnea Severity. Ten-Year Results of the Sleep AHEAD Study. Am J Respir Crit Care Med 2021. PMID 32721163
A newer line of evidence is drug-induced weight loss. In two phase 3 trials of adults with moderate-to-severe OSA and obesity, tirzepatide or placebo was given for 52 weeks. In the trial of people not using positive airway pressure, the AHI fell by 25.3 events per hour with tirzepatide and by 5.3 with placebo (estimated difference -20.0, 95% confidence interval -25.8 to -14.2). In the trial of people already on positive airway pressure, the corresponding changes were -29.3 and -5.5 (difference -23.8). Baseline AHI was about 50 and BMI about 39, the most frequent adverse events were gastrointestinal and mostly mild to moderate, and Eli Lilly funded the trials. This describes a study result in a specific group; whether any medicine is appropriate is a decision for a doctor.
Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024. PMID 38912654
Hypoglossal nerve stimulation, the implanted option
Hypoglossal nerve stimulation uses an implanted device that stimulates the nerve of the tongue during sleep to keep the tongue from blocking the airway. The pivotal STAR study, a single-arm cohort, implanted it in 126 participants with moderate-to-severe OSA who had difficulty accepting or adhering to CPAP (mean age 54.5, mean BMI 28.4, 83% men). At 12 months the median AHI fell 68%, from 29.3 to 9.0 events per hour, and the oxygen desaturation index fell from 25.4 to 7.4. In a randomized withdrawal phase, the AHI rose to 25.8 in the 23 people whose therapy was switched off (from 7.6 while on it), whereas the 23 who kept it stayed at 8.9 (7.2 before). Procedure-related serious adverse events occurred in less than 2%. The study had no control group apart from the short withdrawal phase, and the manufacturer funded it.
Strollo PJ, Soose RJ, Maurer JT, et al. Upper-airway stimulation for obstructive sleep apnea. N Engl J Med 2014. PMID 24401051
The five-year report followed the same cohort: 97 of the 126 completed the protocol and 71 consented to a polysomnogram. The AHI response rate (an AHI below 20 and a reduction of more than 50%) was 75% of those 71, or 63% when the last observation was carried forward for those lost. Serious device-related events, all related to lead or device adjustments, occurred in 6%. The patients in this cohort were chosen: CPAP failure, moderate-to-severe OSA, BMI below 32 and no unfavorable collapse pattern on drug-induced sleep endoscopy. Results are therefore not a statement about everyone with apnea.
Woodson BT, Strohl KP, Soose RJ, et al. Upper Airway Stimulation for Obstructive Sleep Apnea: 5-Year Outcomes. Otolaryngol Head Neck Surg 2018. PMID 29582703
Sleep apnea surgery and what the review found
Sleep apnea surgery covers several different operations. The systematic review, prepared as a companion to an AASM standards paper, looked at maxillomandibular advancement (moving the upper and lower jaw forward), pharyngeal operations such as uvulopharyngopalatoplasty, laser-assisted and radiofrequency procedures, and multilevel procedures. It found that the literature is mostly case series with few controlled trials and varying approaches to evaluation before and after surgery. Substantial and consistent reductions in AHI followed maxillomandibular advancement, with adverse events uncommonly reported. Outcomes after pharyngeal operations were less consistent and adverse events were reported more often, although the review notes that complications were not systematically analyzed. The review described results of newer and multilevel techniques as promising but based on small samples, and called for research on patient selection.
Caples SM, Rowley JA, Prinsell JR, et al. Surgical modifications of the upper airway for obstructive sleep apnea in adults: a systematic review and meta-analysis. Sleep 2010. PMID 21061863
The studies above enrolled different groups of patients, which is why the guidelines place the choice of option after the test and the severity grade.
What SleepTrace can show for the appointment
SleepTrace does not diagnose sleep apnea and does not check how a treatment is working. It listens through the microphone of an iPhone or Android phone, sound only. For a conversation with a doctor it can describe your nights: playable clips of snoring, each with a dB peak and a time, possible breathing pauses marked as timestamps (without a clip), and sleep phases estimated from sound. Its sleep apnea indicator shows a risk level derived from an average event index; it is a screening estimate, meant to prompt a proper test, not to stand in for one. The free plan covers nightly tracking and 3 playable clips a month.
The app does not detect body position, movement or the type of apnea. Keep it open (the screen dims by itself) and the phone on its charger. A sleep study, as the guideline says, remains the standard for diagnosis.
Frequently asked questions
It starts with an objective diagnosis and a severity grade, then a choice among options: positive airway pressure, an oral appliance, positional therapy, weight loss, surgery or a nerve stimulator. The American Academy of Sleep Medicine guideline describes obstructive sleep apnea as a chronic disease that needs long-term, multidisciplinary management, with follow-up after treatment starts.
No. CPAP is the usual first-line treatment, but a guideline from the American Academy of Sleep Medicine and the American Academy of Dental Sleep Medicine recommends that physicians consider an oral appliance for adults who cannot tolerate CPAP or prefer another therapy. Positional devices, weight loss, surgery and a stimulator for the tongue nerve are used in selected groups of patients.
The published evidence covers oral appliances, positional therapy for people whose apnea occurs mostly on the back, weight loss, hypoglossal nerve stimulation in a defined group (moderate to severe apnea, CPAP difficulty, a BMI below 32 in the trial) and upper airway surgery. Which one fits depends on severity, anatomy, weight and sleeping position, assessed by a specialist.
Not reliably. In Sleep AHEAD (264 randomized adults with type 2 diabetes and sleep apnea, 134 of them with a sleep study at 10 years), apnea remission at 10 years was more common after intensive lifestyle intervention (34.4%) than after standard education (22.2%), but the difference in apnea-hypopnea index at 10 years was not statistically significant (4.0 events per hour, P = 0.109). Weight loss lowered severity, and many people still had apnea.
It depends on the operation. A systematic review found that maxillomandibular advancement gave substantial and consistent reductions in the apnea-hypopnea index, while results of pharyngeal operations were less consistent and adverse events were reported more often. The published literature is mostly case series with few controlled trials, so the review called for research on patient selection.
No. The AASM guideline recommends polysomnography or a home sleep apnea test for diagnosis, and advises against diagnosing with questionnaires or prediction tools alone. SleepTrace listens to sound and shows a screening indicator and timestamps of possible breathing pauses, which can describe your nights to a doctor. It does not diagnose and does not replace a sleep test.
SleepTrace is a wellness app, not a medical device. This article is general information, not medical advice. If your symptoms are frequent, severe or worrying, please talk to a doctor.
Treatment depends on a proper test and a severity grade, and an app supplies neither. SleepTrace records sound only, saves snoring clips with a dB peak and a time, marks possible breathing pauses with a timestamp but no clip, and shows a screening indicator. It does not diagnose apnea or judge whether a treatment works; the sleep study and your doctor do that.
Hear your own night. SleepTrace turns a night of audio into your sleep phases, the sounds you made, and how it all trends. Works without a wearable, better with one. Your phone on the nightstand is enough to start. Get it for iPhone or Android →